RESUMEN
Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the Candida spp., Cryptococcus spp., Pneumocystis jirovecii and some lesser-known pathogens. Candida species remain the most common cause of invasive yeast infections (and the most common human pathogenic fungi). These guidelines present evidence-based recommendations for the antifungal management of established, invasive yeast infections in adult and paediatric patients in the haematology/oncology setting. Consideration is also given to the critically ill patient in intensive care units, including the neonatal intensive care unit. Evidence for 'pre-emptive' or 'diagnostic-driven antifungal therapy' is also discussed. For the purposes of this paper, invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections. Specific recommendations for the management of Pneumocystis jirovecii are presented in an accompanying article (see consensus guidelines by Cooley et al. appearing elsewhere in this supplement).
Asunto(s)
Antifúngicos/administración & dosificación , Fiebre de Origen Desconocido/microbiología , Huésped Inmunocomprometido/inmunología , Infecciones Oportunistas/inmunología , Infecciones Oportunistas/microbiología , Adolescente , Adulto , Candidiasis Invasiva/inmunología , Candidiasis Invasiva/prevención & control , Niño , Preescolar , Consenso , Enfermedad Crítica , Criptococosis/inmunología , Criptococosis/prevención & control , Esquema de Medicación , Equinocandinas/administración & dosificación , Medicina Basada en la Evidencia , Fiebre de Origen Desconocido/inmunología , Fluconazol/administración & dosificación , Humanos , Lactante , Unidades de Cuidados Intensivos , Pruebas de Sensibilidad Microbiana , Datos de Secuencia Molecular , Infecciones Oportunistas/prevención & control , Infecciones por Pneumocystis/inmunología , Infecciones por Pneumocystis/prevención & control , Pneumocystis carinii , Guías de Práctica Clínica como AsuntoRESUMEN
BACKGROUND: Human immunodeficiency virus-associated nephropathy (HIVAN) has become the third leading cause of end-stage renal disease (ESRD) in African Americans, and is expected to grow exponentially. Highly active antiretroviral therapy (HAART) has significantly prolonged the survival of patients with HIV infection. Despite the growing number of HIV-positive dialysis patients with prolonged life expectancy, kidney transplantation with immunosuppression has been declined because it is considered a waste of scarce donor kidneys due to potential increases in morbidity and mortality. METHODS: The institutional review board of Drexel University College of Medicine and Hahnemann University Hospital approved this prospective study. The aim was to find out safety and success of kidney transplantation, and the effect of immunosuppression on HIV infection. Forty HIV-positive dialysis patients received kidney transplantation between February 2001 and January 2004. Patient inclusion criteria were maintenance of HAART, plasma HIV-1 RNA of <400 copies/mL, absolute CD4 counts of 200 cells/muL or more. Immunosuppression was basiliximab induction and maintenance with cyclosporine, sirolimus, and steroids. HAART was continued post-transplant. Acute rejections were diagnosed by biopsy and treated with methylprednisolone. Surveillance biopsies were completed at 1, 6, 12, and 24 months, and evaluated for subclinical acute rejection, chronic allograft nephropathy, and HIVAN. RESULTS: One- and 2-year actuarial patient survival was 85% and 82%, respectively, and graft survival was 75% and 71%, respectively. Plasma HIV-1 RNA remained undetectable, and CD4 counts remained in excess of 400 cells per muL with no evidence of AIDS for up to 2 years. CONCLUSION: One- and 2-year graft survival is comparable to other high-risk populations receiving kidney transplantation. One- and 2-year patient survival is higher than HIV patients maintained on dialysis. Immunosuppression does not adversely affect HIV recipients maintained on HAART in the short term.
Asunto(s)
Nefropatía Asociada a SIDA/cirugía , Trasplante de Riñón/métodos , Seguridad , Candidiasis Bucal/prevención & control , Dapsona/uso terapéutico , Femenino , Rechazo de Injerto/inmunología , Seropositividad para VIH/complicaciones , Seropositividad para VIH/inmunología , Humanos , Fallo Renal Crónico/etiología , Fallo Renal Crónico/cirugía , Trasplante de Riñón/inmunología , Trasplante de Riñón/mortalidad , Masculino , Persona de Mediana Edad , Nistatina/uso terapéutico , Infecciones por Pneumocystis/prevención & control , Estudios Retrospectivos , Virus del Sarcoma del Mono Lanudo , Análisis de Supervivencia , Resultado del TratamientoAsunto(s)
Humanos , Infecciones Fúngicas del Sistema Nervioso Central/patología , Enfermedades Pulmonares Fúngicas/patología , Micosis , Neumonía por Pneumocystis/diagnóstico , Infecciones por Pneumocystis/prevención & control , Pneumocystis carinii/patogenicidad , Diagnóstico Clínico , Técnicas de Laboratorio ClínicoRESUMEN
The use of alternative treatments for HIV disease was assessed before and after the introduction of highly active antiretroviral therapy (HAART) by the use of a standardised questionnaire. These data were related to epidemiological, clinical and laboratory parameters and compliance levels to recommended antiretroviral and anti-Pneumocystis carinii regimens. Compared with the 476 evaluable patients interviewed during the first 9 months of 1996, the 549 evaluable subjects screened in January-September 1998 showed less frequent recourse to alternative treatments (22.8 vs. 35.7% of patients; P < 0.001). A significant correlation between use of alternatives, poor compliance to antiretroviral drugs and anti-P. carinii chemoprophylaxis and clinical and immunological progression of HIV disease was shown in 1996, but was not maintained in 1998. No relevant differences were found in the selection of most non-conventional treatments and in the number of strategies followed and their duration of use. Unorthodox treatments were used by most patients concurrently rather than instead of official therapeutic regimens. No correlation was found between the use of alternative treatment and the patients' age, gender, type of risk for HIV disease and duration of HIV seropositivity. The correlations between alternative and official treatments for HIV disease before and during the HAART era shows that a considerable percentage of patients still resort to alternatives in 1998 compared with 1996 but that this does not interfere with compliance with recommended pharmacological regimens or the progression of the disease.
Asunto(s)
Terapias Complementarias , Infecciones por VIH/terapia , Fármacos Anti-VIH/uso terapéutico , Antifúngicos/uso terapéutico , Recolección de Datos , Quimioterapia Combinada , Infecciones por VIH/tratamiento farmacológico , Humanos , Infecciones por Pneumocystis/tratamiento farmacológico , Infecciones por Pneumocystis/epidemiología , Infecciones por Pneumocystis/prevención & control , Infecciones por Pneumocystis/terapiaRESUMEN
Artemisinin and its derivatives have been found effective in vivo against Plasmodium and in vitro against Toxoplasma gondii and Pneumocystis carinii. We tested the activity of artemether for prophylaxis and treatment in the rat model of concurrent T. gondii and P. carinii infection. Artemether at doses of 18 and 100 mg/kg administered (s.c.) in prophylaxis did not prevent toxoplasmosis or pneumocystosis, while trimethoprimsulfamethoxazole (reference treatment) was effective for prevention of both infections. Similar results were obtained in curative studies. These results do not support the use of artemether for prevention or treatment of toxoplasmosis or pneumocystosis.